Nexavar is a targeted oral anticancer agent that inhibits several receptor tyrosine kinases involved in tumor growth signaling. It is primarily used in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The drug acts as a selective inhibitor of vegfr, pdgfr, and fgfr, blocking downstream pathways that promote cell proliferation. By binding to the atp-binding sites of these kinases it prevents phosphorylation of downstream effectors. This inhibition reduces vascular endothelial growth factor mediated angiogenesis and interferes with tumor cell survival signals. The pharmacodynamic effect of Nexavar leads to decreased tumor blood flow and growth inhibitory activity in affected tissues. Systemic absorption after oral administration allows sustained concentration-dependent inhibition of multiple kinases.

Nexavar is a small molecule targeted therapy used primarily for certain cancers. It is indicated for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The drug functions as a dual inhibitor of the receptor tyrosine kinases vegfr pdgfr and raf. By blocking these kinases Nexavar interferes with signaling pathways that promote tumor cell proliferation and angiogenesis. This inhibition leads to reduced blood vessel formation within tumors limiting their nutrient supply and growth. Consequently Nexavar helps slow disease progression and improve patient outcomes in the settings where it is prescribed.

Nausea is a frequent side effect of Nexavar observed in clinical trials. Fatigue and weakness are also commonly reported by patients. Diarrhea may occur in some individuals taking the medication. Skin rash or itching can develop as a dermatological reaction. Elevated liver enzymes are detected through routine blood tests. Headache and loss of appetite are additional symptoms noted in patient reports.

Common side effects of Nexavar include changes in appetite. Some patients experience skin rash or dryness. Fatigue is frequently reported during treatment. Diarrhea or abdominal pain may occur. Headache and elevated blood pressure are also observed. Nausea and vomiting can be managed with supportive care. Laboratory tests often show changes in liver enzymes over time.